权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

HUMAN C MYC GENE REPLICATION ORIGIN

人类 C MYC 基因复制起源

基本信息

批准号：
6519707
负责人：
Michael LEFFAK
金额：
$ 29.08万
依托单位：
WRIGHT STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1996
资助国家：
美国
起止时间：
1996-03-01 至 2004-06-30
项目状态：
已结题

项目摘要

The process of DNA replication is the primary physiological target for anti-proliferative drugs used to treat cancer. The broad goal of our work is to characterize the major cell cycle regulated step in mammalian DNA replication, the activation of origins to initiate DNA synthesis. Our experiments focus on the human c-myc replication origin. Understand the function of DNA elements in the c-myc origin is likely to give new insight into the regulation of DNA metabolism by mechanisms that control cell division in normal and disease states. The c-myc origin is one of a limited number of chromosomal origins identified in metazoans, and the only origin to replicate autonomously in plasmids in transfected cells and in vitro at chromosomal initiation sites. To test the effects of mutations on c-myc origin activity in the chromosomes of intact cells, we have developed an innovative system based on the S. cerevisae FLP recombinase for the site-specific integration of DNA in human cells. This system is highly efficient, and reproducibly targets c-myc origin constructs with precision to specific genomic acceptor sites. The FLP recombinase system is extremely flexible in the range of constructs that can be tested in an in vivo chromosomal environment. Hence, the system is not limited to the analysis of DNA replication but is broadly applicable to the study of other aspects of DNA metabolism. Using the FLP system we will test the hypothesis that the c-myc origin compromises preferred start sites for DNA synthesis and that initiation at these sites depends on cis-acting replicator elements. In each of three Specific Aims a panel of c-myc origin constructs will be integrated at defined chromosomal acceptor sites and the structure and replication activity at those sites before and after integration of the wild type and mutated origins will be assessed. Aim 1 will creative progressive 5' or 3' deletions of the origin, and mutations in specific candidate replicator elements, for analysis of origin activity. Aim 2 will test directly whether c-myc origin activity or replication timing is affected by an active transcription unit or telomere position effects. Aim 3 will test whether replication timing is affected by an active transcription unit or telomere position affects. Aim 3 will test whether there are multiple preferred start sites for the initiation of DNA synthesis in the c-myc origin that are subservient to a cis-acting replicator. Origin activity and structure will be analyzed by competitive PCR, PCR mapping of nascent DNA strands, DNase digestion, chemical footprinting, and ligation-mediated PCR.

DNA复制过程是用于治疗癌症的抗增殖药物的主要生理靶点。我们工作的主要目标是表征哺乳动物DNA复制中主要的细胞周期调控步骤，即启动DNA合成的起始点的激活。我们的实验集中在人类c-myc复制起点。了解c-myc起源中DNA元件的功能可能会对正常和疾病状态下控制细胞分裂的机制对DNA代谢的调节产生新的见解。c-myc起源是在后生动物中鉴定的有限数量的染色体起源之一，并且是在转染细胞中的质粒中和在体外在染色体起始位点处自主复制的唯一起源。为了测试突变对完整细胞染色体中c-myc起源活性的影响，我们开发了一种基于S. cerevisae FLP重组酶用于DNA在人细胞中的位点特异性整合。该系统是高效的，并且可重复地将c-myc起源构建体精确地靶向特定的基因组受体位点。FLP重组酶系统在可以在体内染色体环境中测试的构建体范围内是极其灵活的。因此，该系统不仅限于DNA复制的分析，而且广泛适用于DNA代谢的其他方面的研究。使用FLP系统，我们将测试的假设，c-myc起源妥协的DNA合成的首选起始位点，并在这些网站的启动取决于顺式作用的复制元件。在三个特定目的中的每一个中，一组c-myc起点构建体将被整合在定义的染色体受体位点处，并且将评估野生型和突变起点整合之前和之后在这些位点处的结构和复制活性。目的1将创造性地进行起源的5'或3'缺失，以及特定候选复制子元件的突变，用于分析起源活性。目的2将直接测试是否c-myc的起始活性或复制时间是由一个活跃的转录单位或端粒位置效应的影响。目的3将测试复制时间是否受到活性转录单位或端粒位置的影响。目的3将测试是否有多个优选的起始位点的起始DNA合成的c-myc的起源是从属于一个顺式作用的复制子。将通过竞争性PCR、新生DNA链的PCR作图、DNA酶消化、化学足迹法和连接介导的PCR分析起源活性和结构。